Stock INTI INHIBITOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Inhibitor Therapeutics, Inc.

Equities

INTI

US45720M1053

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 11:24:23 2024-05-09 EDT 		5-day change 1st Jan Change
0.1206 USD -7.22% Intraday chart for Inhibitor Therapeutics, Inc. +2.20% +31.09%
03-29 Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 22.2 20.65 13.06 56.43 37.21 15.83
Enterprise Value (EV) 1 21.09 19.85 13.08 56.63 25.67 6.986
P/E ratio -4.71 x -7.04 x -10.3 x -113 x 3.29 x -4.6 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF -10.9 x -11.6 x -28.5 x -483 x -42.6 x -3.88 x
FCF Yield -9.2% -8.66% -3.51% -0.21% -2.35% -25.8%
Price to Book -5.65 x -3.18 x -1.78 x -7.44 x 2.04 x 3 x
Nbr of stocks (in thousands) 369,959 370,446 373,636 376,858 376,858 172,024
Reference price 2 0.0600 0.0558 0.0350 0.1498 0.0988 0.0920
Announcement Date 19-03-07 20-03-30 21-03-26 22-03-30 23-03-31 24-03-29
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - - - - - -
EBIT 1 -4.564 -2.748 -1.059 -0.3254 -0.6579 -3.405
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -4.55 -2.733 -1.058 -0.2986 12.16 -3.026
Net income 1 -4.55 -2.733 -1.058 -0.2986 12.11 -3.026
Net margin - - - - - -
EPS 2 -0.0127 -0.007918 -0.003383 -0.001325 0.0300 -0.0200
Free Cash Flow 1 -1.94 -1.718 -0.4586 -0.1173 -0.6023 -1.802
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-03-07 20-03-30 21-03-26 22-03-30 23-03-31 24-03-29
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 0.02 0.2 - -
Net Cash position 1 1.11 0.8 - - 11.5 8.84
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.94 -1.72 -0.46 -0.12 -0.6 -1.8
ROE (net income / shareholders' equity) -4,575% 219% 35.9% 8.56% 518% -44.6%
ROA (Net income/ Total Assets) -285% -161% -128% -213% -6.83% -20.3%
Assets 1 1.596 1.697 0.8245 0.1399 -177.1 14.88
Book Value Per Share 2 -0.0100 -0.0200 -0.0200 -0.0200 0.0500 0.0300
Cash Flow per Share 2 0 0 0 0 0.0700 0.0500
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 19-03-07 20-03-30 21-03-26 22-03-30 23-03-31 24-03-29
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INHIBITOR THERAPEUTICS, INC. Stock Inhibitor Therapeutics, Inc.
+31.09% 22.36M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.97% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.21% 105B
ARGENX SE Stock argenx SE
+1.57% 23.46B
BIONTECH SE Stock BioNTech SE
-12.77% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.50% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.00% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.20% 12.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. INTI Stock
  4. Financials Inhibitor Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW